HomeNew Products

New Products

Cat.No. Product Name Information Added
E6726 N-Hydroxysuccinimide Feb 01 2026
A2177 Anti-mouse IFNγR (CD119)-Invivo Anti-mouse IFNγR (CD119)-Invivo reacts with the mouse IFNγR (interferon gamma receptor) α chain also known as CD119 and IFNγ receptor 1. CD119 heterodimerizes with IFNγ receptor 2 (AF-1) to form the IFNγR, a Class II cytokine receptor. Jan 26 2026
A2178 Anti-mouse/human IL-5-Invivo Anti-mouse/human IL-5-Invivo reacts with mouse and human interleukin-5 (IL-5), a 26 kDa homodimeric cytokine. IL-5 stimulates B lymphocyte differentiation and proliferation and increases the secretion of IgM and IgA. Jan 26 2026
E1822 Acoramidis hydrochloride Acoramidis hydrochloride (AG10 hydrochloride) is an orally active, selective kinetic stabilizer of WT-transthyretin (TTR) and V122I mutant transthyretin (TTR), providing effective treatment for transthyretin amyloid cardiomyopathy (ATTR-CM). Jan 22 2026
E6699 Opiranserin hydrochloride Opiranserin hydrochloride (VVZ-149 hydrochloride) is a non-opioid and non-NSAID analgesic that acts as a dual antagonist of glycine transporter type 2 (GlyT2) and serotonin receptor 2A (5HT2A), with IC50 of 0.86 μM and 1.3 μM, respectively. Jan 22 2026
S9883 RMC-5552 RMC-5552 is a selective bi-steric inhibitor of mTORC1, with the potential for treating mTORC1-activated tumors. It potently inhibits mTORC1-mediated phosphorylation of pS6K and p4EBP1 with IC50 values of 0.14 nM and 0.48 nM, respectively. Jan 22 2026
A2176 Anti-mouse CD8α (53-6.7)-Invivo Anti-mouse CD8α (53-6.7)-Invivo reacts with mouse CD8α. The CD8 antigen is a transmembrane glycoprotein that acts as a co-receptor for the T cell receptor (TCR). Jan 20 2026
E6671 CMPD-39 CMPD-39 (Compound 39) is a selective non-covalent inhibitor of USP30 with an IC50 of ~20 nM in in vitro enzyme assays. Jan 19 2026
E6515 ML-60218 ML-60218 is a broad-spectrum inhibitor of RNA polymerase III (pol III), with an IC50 of 32 μM for Saccharomyces cerevisiae and 27 μM for human pol III. ML-60218 disrupts pre-assembled viroplasms and impedes the formation of new ones, acting independently of de novo transcription of cellular RNAs. Jan 19 2026
F5127 CNBP Antibody [E10D2] Jan 16 2026
F4751 Phospho-MEK1 (Ser298) Antibody [L22P14] Jan 16 2026
P1262 Eloralintide (LY-3841136) Eloralintide (LY 3841136) is an AMYR agonist with potential applications in type 2 diabetes and obesity research. Jan 14 2026
E6411 RP03707 RP03707 is a PROTAC molecule designed to degrade KRASG12D, consisting of three components: a KRASG12D inhibitor (, red), a linker (black), and an E3 ligase ligand (blue). Jan 14 2026
E6653 AR-C118925XX AR-C118925XX is a P2Y2 receptor antagonist. It reduces ATP-induced IL-6 production and p38 phosphorylation. In mice, AR-C118925XX attenuates Bleomycin -induced dermal fibrosis. Additionally, it suppresses ATP-stimulated tumor growth. Jan 14 2026
E6651 HGC652 HGC652 is a TRIM21-dependent molecular glue degrader that binds the E3 ubiquitin ligase TRIM21 (Kd ≈ 0.06 µM) to induce a TRIM21–NUP98 ternary complex, driving the ubiquitination and selective degradation of nuclear pore complex proteins like NUP155, leading to nuclear pore collapse and cancer cell death. Jan 14 2026
P1269 Pegcetacoplan acetate Pegcetacoplan acetate, a PEGylated cyclic peptide, is the first approved inhibitor of complement component C3/C3b designed to treat adults with Paroxysmal Nocturnal Hemoglobinuria (PNH). It binds C3 and C3b to inhibit convertase-mediated C3 cleavage, blocking C3b opsonization (extravascular hemolysis) and downstream MAC formation (intravascular hemolysis). Jan 13 2026
E8319 Ro 48-8071 fumarate Ro 48-8071 fumarate is a potent, selective inhibitor of 2,3-oxidosqualene cyclase (OSC) (IC50 = 6.5 nM), a key enzyme downstream of HMG-CoA reductase that catalyzes lanosterol formation in cholesterol biosynthesis. It reduces intracellular cholesterol levels without the feedback upregulation of HMG-CoA reductase seen with statins, providing a distinct, self-limiting regulatory loop for lowering LDL-C. Additionally, it also exhibits significant anti-cancer properties by inducing apoptosis and disrupting cell signaling in cancer models. Jan 13 2026
F4944 SCG10/Stathmin-2 Antibody [D11B18] Jan 12 2026
F4375 Na+/H+ Exchanger-1 Antibody [K9D3] Jan 12 2026
E6564 VG-3927 VG‐3927 is a potent, selective, and brain-penetrant agonist of TREM2 that induces anti-inflammatory microglial activation and has the potential to treat Alzheimer's disease (AD). Jan 12 2026
E8330 NIC3 NIC3 is a selective inhibitor of nucleus accumbens-associated protein 1 (NAC1), a BTB/POZ domain-containing transcription corepressor overexpressed in cancers. It binds the conserved Leu-90 residue in NAC1's BTB domain, disrupting homodimerization essential for nuclear body formation and stability. Jan 05 2026
E8325 Quadrol Quadrol (N,N,N′,N′-Tetrakis(2-hydroxypropyl)ethylenediamine, EDTP) is an immunostimulant which is considered as a potentially useful active molecule for accelerating wound healing. Quadrol can form a complex with Ca²⁺, mediate the entry of Ca²⁺ into macrophages, and stimulate macrophage activation. Jan 05 2026
E8327 DHBS DHBS (Sodium 3,5-dichloro-2-hydroxybenzenesulphonate) is used in conjunction with 4-aminoantipyrine (4-AAP) and hydrogen peroxide (H2O2) for chromogenic quantitation of uric acid in serum and urine samples. Jan 05 2026
E6635 MC3138 MC3138 is a selective activator of SIRT5 and inhibits proliferation in SIRT5-low PDAC cell lines and organoids by restoring SIRT5-mediated desuccinylation and deacetylation. Jan 04 2026
E0853 360A 360A stabilizes G-quadruplex structures and inhibits telomerase activity, showing an IC50 of 300 nM in TRAP-G4 assays. Dec 31 2025
A2175 Anti-mouse CD11c-Invivo Anti-mouse CD11c-Invivo reacts with mouse CD11c, the most widely used defining marker for murine dendritic cells (DCs). CD11c is also known as integrin alpha-X (Itgax) and CD11 antigen-like family member C. Dec 30 2025
E6667 JNJ-9350 JNJ-9350 is a chemical probe that inhibits spermine oxidase (SMOX) with an IC50 of 0.01 μM. This compound also shows inhibitory activity against polyamine oxidase (PAO), exhibiting an IC50 of 0.79 μM. JNJ-9350 has potential applications in cancer research. Dec 24 2025
E8329 VQW-765 VQW-765 (AQW-051) is an orally active agonist targeting the alpha-7 nicotinic acetylcholine receptor (α7-nAChR), exhibiting a pKD of 7.56 for the human recombinant α7-nAChR. This compound demonstrates anxiolytic-like activity in animal models. VQW-765 has potential applications in anxiety disorder and acute performance anxiety studies. Dec 24 2025
E1789 Asundexian Asundexian (BAY 2433334) is an orally administered inhibitor of coagulation factor XIa (FXIa). It binds reversibly to the FXIa active site with high affinity, blocking its enzymatic function. In buffer systems, asundexian exhibits an IC50 of 1 nM against human FXIa. Dec 24 2025
E6656 STAT3-IN-13 STAT3-IN-13 (compound 6f) is a STAT3 inhibitor. It exhibits anti-proliferative activity and binds to the STAT3 SH2 domain with a KD of 0.46 μM. This compound inhibits STAT3 Y705 phosphorylation and downstream target gene expression. In vitro studies show STAT3-IN-13 induces apoptosis, while in vivo experiments demonstrate its ability to suppress tumor growth and metastasis. STAT3-IN-13 has potential applications in cancer research. Dec 24 2025
E5872 BBO-10203 BBO-10203 inhibits PI3Kα and KRASG12C by covalently binding to Cys242 in the PI3Kα RAS-Binding Domain. It inhibits both GTP-bound and GDP-bound KRASG12C states, with IC50 and EC50 values of 0.031 nM and 0.02 nM respectively. This compound interferes with RAS-PI3Kα interaction, suppressing RAS-dependent PI3Kα activation. It decreases pERK levels, inhibits cell proliferation, and causes G1 phase arrest and apoptosis. BBO-10203 has potential applications in breast cancer, colorectal cancer, and non-small cell lung cancer research. Dec 24 2025
E8324 GE11 GE11 is an active peptide that binds with colloidal drug delivery systems, serving as smart carriers for antitumor drugs in cancer research. Dec 21 2025
E0850 DPhPC DPhPC is a phosphatidylcholine (PC) derivative employed in the synthesis of bilayer vesicle phospholipids. The DPhPC bilayer membranes exhibit minimal ion leakage in the absence of pores or ion channels, making them suitable for investigating ion channel activity and membrane potential regulation. DPhPC-based nanoliposomes (NTG) enhance nitric oxide (NO) bioavailability and demonstrate anti-inflammatory properties. Dec 14 2025
F4670 Keratin 18 Antibody [M2J10] Dec 12 2025
F4438 GPX1/2 Antibody [L20K22] Dec 12 2025
F4192 Caspase-1 Antibody [C2H20] Dec 12 2025
F2860 Phospho-NAK/TBK1 (Ser172) Antibody [G18L12] NAK/TBK1 (phospho S172),Phospho-TBK1/NAK (Ser172) Dec 12 2025
F4919 Myc tag Antibody [A14H15] Dec 12 2025
E8323 Emeramide Emeramide functions as a thiol-based redox antioxidant and chelates heavy metals. Dec 10 2025
E0848 Pinealon Pinealon is a tripeptide exhibiting neuroprotective effects. This peptide inhibits reactive oxygen species (ROS) buildup and blocks ERK 1/2 activation. It enhances functional activity of key brain tissue cellular components while decreasing spontaneous cell death rates. Studies demonstrate Pinealon's protective effects against prenatal hyperhomocysteinemia in rat offspring. Dec 10 2025
E6646 BMS-986260 BMS-986260 is an orally active immuno-oncology agent that inhibits TGFβR1 with an IC50 of 1.6 nM. It shows selectivity for TGFβR1 compared to TGFβR2 and over 200 other kinases. In MINK and NHLF cell lines, BMS-986260 blocks TGFβ-induced pSMAD2/3 nuclear translocation with IC50 values of 350 nM and 190 nM, respectively. Dec 09 2025
E6560 naperiglipron Naperiglipron (LY3549492) (Example 2) acts as a glucagon-like peptide 1 receptor (GLP-1R) agonist, exhibiting an EC50 of 1.14 nM at hGLP-1R. In GLP-1R knock-in mouse models, it reduces blood glucose levels. The compound shows PDE10A1 enzyme inhibitory activity (IC50: 7.43 μM) and displays weak hERG inhibition. Naperiglipron has potential applications in type II diabetes mellitus (T2DM) and obesity studies. Dec 08 2025
E6639 Auceliciclib (AU3-14,Ulecaciclib ) Ulecaciclib is an orally active cyclin-dependent kinase (CDK) inhibitor with Ki values of 0.62 μM for CDK2/Cyclin A, 0.2 nM for CDK4/Cyclin D1, 3 nM for CDK6/Cyclin D3, and 0.63 μM for CDK7/Cyclin H. This compound demonstrates blood-brain barrier penetration and favorable pharmacokinetic properties. Dec 04 2025
P1231 Mazdutide (IBI362, LY330567) Mazdutide (IBI-362; LY-3305677) is a synthetic long-acting oxyntomodulin analog that functions as a dual agonist of glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR). The compound exhibits binding affinity for human and mouse GCGR (Ki values of 17.7 nM and 15.9 nM, respectively) and GLP-1R (Ki values of 28.6 nM and 25.1 nM, respectively). In mouse islets, mazdutide stimulates insulin secretion with an EC50 of 5.2 nM. This agent has been investigated in research related to obesity and type 2 diabetes (T2D). Dec 04 2025
E6643 SS-3091 SS-3091 is a pan-KRas inhibitor that targets the interaction interfaces of KRas. By destabilizing the ARaf/KRas complex, it modulates downstream signaling pathways. This compound exhibits activity against KRas G12D, G12C, G12V, and G12S mutants in multiple cancer cell lines. Dec 04 2025
E5927 Mito-LND (Mito-Lonidamine) Mito-LND (Mito-Lonidamine) is a mitochondria-targeted derivative of lonidamine conjugated with a triphenylphosphonium cation that selectively accumulates in cancer cell mitochondria due to their high membrane potential. It potently inhibits oxidative phosphorylation (OXPHOS) by disrupting respiratory complexes I and II, stimulating ROS production and Prx3 oxidation while suppressing AKT/mTOR/p70S6K signaling. Dec 04 2025
E6511 ADT-1004 ADT-1004 is an orally bioavailable prodrug of ADT-007, that acts as a first-in-class selective inhibitor of pan-RAS with potent antitumor activity in pancreatic ductal adenocarcinoma (PDAC) models. Dec 04 2025
E6526 MCB-294 MCB-294 is a pan-KRAS inhibitor that targets both active (GTP-bound) and inactive (GDP-bound) KRAS states, exhibiting Kd values of about 1 pM and 10 nM, respectively. It shows preferential inhibition of KRAS over NRAS and HRAS. The compound inhibits proliferation of hTERT-HPNE cells harboring G12D, G12C, G12V, G12S, G13D, and wild-type KRAS variants, with IC50 values around 700 nM. MCB-294 triggers apoptosis in KRAS-mutated tumors and demonstrates activity against KRASG12C inhibitor-resistant cancer cells while modulating the tumor immune microenvironment. This compound serves as a research tool for pancreatic, colorectal, and lung cancer investigations. Dec 04 2025
E5936 FT895 FT895 inhibits HDAC11 with an IC50 of 3 nM. Dec 04 2025
E6647 Bireociclib (XZP-3287,CDK4/6-IN-2) CDK4/6-IN-2 is a CDK4 and CDK6 inhibitor obtained from patent US20180000819A1 (Compound 1). It exhibits IC50 values of 2.7 nM for CDK4 and 16 nM for CDK6. Dec 04 2025
E6638 VS-7375 (GFH375) VS-7375 (GFH375) is an oral small-molecule inhibitor that selectively targets KRAS G12D in both its active (GTP-bound) and inactive (GDP-bound) forms. This dual-state inhibition results in stronger tumor suppression compared to single-state inhibitors. It exhibits potent anti-proliferative and anti-tumor effects in KRAS G12D-mutant models, including an intracranial GP2D tumor model. Dec 04 2025
E6517 PKN1 PKN1/2-IN-1 is a cell-permeable compound that inhibits PKN1 and PKN2, with IC50 values of 16 nM and 210 nM, and Ki values of 8 nM and 108 nM, respectively. In NanoBRET assays, it shows intracellular PKN2 binding with an IC50 of 2.1 μM. This compound is applicable for investigating tumor cell migration and related physiological processes. Dec 02 2025
E6521 HRS‑5346 Lp(a)-IN-5 (Compound A) is an orally administered lipoprotein(a) (Lp(a)) inhibitor. This compound demonstrates inhibition of Apo(a) and ApoB protein assembly with an IC50 of 0.41 nM. It may be useful for studying diseases associated with increased plasma Lp(a) levels, including cardiovascular disorders. Dec 02 2025
E6578 AS1708727 AS1708727 is an orally bioavailable Foxo1 inhibitor that exhibits EC50 values of 0.33 μM against G6Pase and 0.59 μM against PEPCK. Dec 02 2025
E6498 Atebimetinib (IMM-1-104) Atebimetinib inhibits MEK tyrosine kinase and demonstrates antineoplastic effects. Dec 02 2025
E6636 DY268 DY268 is a farnesoid X receptor (FXR) antagonist with an IC50 of 7.5 nM. In cellular assays, it inhibits FXR transactivation with an IC50 of 468 nM. This compound has applications in drug-induced liver injury (DILI) research. Nov 25 2025
E6634 Thiethylperazine Thiethylperazine is a phenothiazine derivative that acts as an oral dopamine D2-receptor and histamine H1-receptor antagonist. This compound functions as an ABCC1 activator and has been shown to decrease amyloid-β (Aβ) accumulation in mice. It exhibits anti-emetic, antipsychotic, and antimicrobial properties. Nov 25 2025
E6565 Ofirnoflastum Ofirnoflast (Ofirnoflastum) inhibits serine/threonine-protein kinase Nek7 and exhibits anti-inflammatory activity. Nov 24 2025
E6572 AD1058 AD1058 is an orally bioavailable ATR inhibitor with blood-brain barrier permeability (IC50 = 1.6 nM). It demonstrates antitumor effects through inhibition of tumor cell proliferation, induction of cell cycle arrest, and promotion of apoptosis. This compound is applicable for studies involving advanced malignancies and brain metastases. Nov 24 2025
E6588 LY3509754 LY3509754 (IL-17A inhibitor 1) inhibits IL-17A, showing IC50 values of <9.45 nM in alphalisa assay and 9.3 nM in HT-29 cells. Nov 24 2025
E4617 Gly-β-MCA Gly-β-MCA is a bile acid derivative that functions as a stable, orally active, and intestine-specific farnesoid X receptor (FXR) antagonist with potential therapeutic applications in metabolic diseases. Nov 21 2025
E1219 CSN5i-3 CSN5i-3 is a selective, orally bioavailable CSN5/Jab1 inhibitor that demonstrates potent activity in suppressing CSN-mediated Cul1 deneddylation, exhibiting an IC50 of 5.8 nM. Nov 21 2025
E8318 T6167923 T6167923 is a selective MyD88-dependent signaling pathway inhibitor that directly interacts with the Toll/IL-1 receptor (TIR) domain of MyD88, preventing its homodimerization. This compound demonstrates inhibitory effects on NF-κB-mediated Staphylococcus enterotoxin AP (SEAP) activity and exhibits anti-inflammatory properties, with IC50 values of 2.7 μM (IFN-γ), 2.9 μM (IL-1β), 2.66 μM (IL-6), and 2.66 μM (TNF-α). Nov 21 2025
E1892 FM4-64 FM4-64 is a highly lipophilic yet water-soluble styryl dye that specifically binds to cellular membranes and intracellular organelles, generating fluorescence. This compound serves as a valuable marker for studying endocytic and exocytic membrane structures. Nov 21 2025
E1162 GLPG0974 GLPG0974 is a potent antagonist of free fatty acid receptor-2 (FFA2/GPR43), exhibiting an IC50 value of 9 nM. Nov 21 2025
E1888 NIM811 ((Melle-4)cyclosporin) NIM811 ((Melle-4)cyclosporin; SDZ NIM811) is an orally administered dual inhibitor targeting mitochondrial permeability transition and cyclophilin, demonstrating strong in vitro antiviral activity against hepatitis C virus (HCV) . Nov 21 2025
E4757 Setidegrasib (ASP3082) Setidegrasib (KRAS G12D inhibitor 17, ASP3082) is a PROTAC-based KRAS degrader (DC50 = 37 nM) that specifically targets G12D-mutated KRAS protein for degradation. It demonstrates potent inhibition of p-ERK, p-AKT, and p-S6 signaling pathways in AsPC-1 cells. The compound shows significant antitumor efficacy across multiple murine xenograft models. Setidegrasib serves as a research tool for investigating KRAS(G12D)-driven solid tumors. (Blue: VHL ligand ; Black: linker ; Pink: G12D-targeting moiety ). Nov 20 2025
E5832 BBI-2779 BBI-2779 is a potent, selective, and orally active inhibitor of CHK1 with an IC50 of 0.3 nM. It preferentially kills cancer cells containing extrachromosomal DNA (ecDNA) by inducing replication stress and cell death. In gastric cancer models with FGFR2 gene amplification on ecDNA, BBI-2779 suppresses tumor growth and prevents drug resistance. Nov 20 2025
E5858 Chiglitazar (Carfloglitazar) Chiglitazar (Carfloglitazar) is a potent dual agonist of PPARα and PPARγ with EC50 values of 1.2 μM and 0.08 μM, respectively, and also activates PPARδ with an EC50 of 1.7 μM. It effectively improves insulin resistance and corrects dyslipidemia in monosodium L-glutamate (MSG)-induced obese rats. Nov 20 2025
E5859 Acivicin hydrochloride Acivicin hydrochloride (AT-125 hydrochloride) is the hydrochloride salt of Acivicin, a natural antibiotic produced by Streptomyces sviceus. It is a potent inhibitor of γ-glutamyl transpeptidase (GGT), an enzyme that initiates glutathione catabolism to cysteine. Acivicin also exhibits anti-cancer and anti-parasitic properties. Nov 20 2025
E5860 20-HETE 20-HETE (20-Hydroxyeicosatetraenoic acid) is a cytochrome P450-derived metabolite of arachidonic acid that plays a dual role in blood pressure regulation. It lowers blood pressure by inhibiting sodium reabsorption and promoting natriuresis in the kidneys, but also raises blood pressure by sensitizing vascular smooth muscle to constrictors, increasing myogenic tone, and inducing endothelial dysfunction. Additionally, 20-HETE stimulates endothelial angiotensin-converting enzyme (ACE), activating a prohypertensive renin-angiotensin-aldosterone system (RAAS) feedback loop that contributes to hypertension and vascular remodeling. Nov 20 2025
E1983 BAY-850 BAY-850 is a potent and isoform-selective inhibitor of the ATPase family AAA domain-containing protein 2 (ATAD2) bromodomain, with an IC50 of 166 nM in TR-FRET assays. It induces ATAD2 bromodomain dimerization and effectively blocks its interaction with acetylated histones in vitro. Nov 20 2025
E2989 AZD5904 AZD5904 is a selective and irreversible human Myeloperoxidase (MPO) inhibitor. AZD5904 reduces 3-chlorotyrosine-modified MYBPC3 levels, restores MYBPC3 phosphorylation, and alleviates the calcium signalling and relaxation defects. Nov 20 2025
E5915 Moracin O Moracin O is a 2-arylbenzofuran isolated from the Morus alba Linn. Moracin O demonstrates potent in vitro inhibitory activity against hypoxia-inducible factor (HIF-1) with an IC50 value of 6.76 nM in a cell-based HRE assay. Moracin O attenuates reactive oxygen species (ROS) generation triggered by oxygen-glucose deprivation (OGD). Moracin O also exhibits neuroprotective and anti-inflammatory effects. Nov 20 2025
E5946 C12FDG C12FDG (5-Dodecanoylaminofluorescein di-β-D-galactopyranoside) is a lipophilic green fluorescent probe used to detect β-galactosidase activity. C12FDG demonstrates greater sensitivity for measuring β-galactosidase activity in animal cells than fluorescein di(β-D-galactopyranoside). Nov 20 2025
E4747 BMS-986408 BMS-986408 is a first-in-class dual inhibitor of DGKα and DGKζ, exhibiting IC₅₀ values of 0.0003 μM and 0.002 μM for DGKα and DGKζ lipid kinase activity, respectively. It potentiates T cell–receptor signaling and T-cell activation, enhancing the effectiveness of both PD-1 and CAR T-cell therapy in preclinical models. Nov 20 2025
E6600 3FAx-Neu5Ac 3Fax-Neu5Ac is a fluorinated sialic acid analogue that inhibits sialyltransferase activity, reduces cellular sialylation, and leads to decreased MHC expression and suppression of myoblast fusion, thereby demonstrating potential in regulating skeletal muscle cell differentiation. Nov 20 2025
E6603 USP5-IN-1 USP5-IN-1 (compound 64) is a selective competitive inhibitor of USP5 zinc finger ubiquitin binding domain (ZnF-UBD) with a Kd of 2.8 μM. It competitively blocks ubiquitin binding to the ZnF-UBD domain, suppressing USP5 catalytic activity and ubiquitin chain hydrolysis, with potential applications as a chemical probe and therapeutic agent in USP5-related cancers. Nov 20 2025
E6614 FABPs ligand 6 (MF6) FABPs ligand 6 (MF6) is a potent dual inhibitor of FABP5 and FABP7 with KD values of 874 nM and 20 nM, respectively. It rescues mitochondrial function and mitigates FABP5/FABP7-mediated injury, demonstrating potential therapeutic effects in multiple sclerosis (MS). Nov 20 2025
E6610 GPX4-IN-5 GPX4-IN-5 covalently inhibits GPX4 with an IC50 of 0.12 μM. This compound induces ferroptosis and exhibits anti-tumor activity. It has potential applications in triple-negative breast cancer (TNBC) research. Nov 20 2025
E2949 Talarozole (R115866) Talarozole (R115866) is a potent, orally active inhibitor of cytochrome P450 (CYP26)-mediated metabolism of All-trans-retinoic acid (RA). It inhibits the conversion of RA by CYP26, with an IC50 of 0.004 µM, and enhances endogenous RA levels and All-trans-retinoic acid receptor (RAR) activation, showing potential as a targeted agent for dermatological therapy. Nov 20 2025
E1154 DS18561882 DS18561882 is a potent, isozyme-selective, and orally available inhibitor of methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) with an IC50 value of 0.0063 μM. It exhibits complete tumor growth inhibition in a mouse xenograft model, and shows potential as an anti-cancer agent. Nov 20 2025
P1253 Allo-aca (ARV-1803) Allo-aca (ARV-1803) is a synthetic peptide that functions as a specific antagonist of the leptin receptor, effectively blocking leptin signaling in both in vitro and in vivo. It also demonstrates potential therapeutic applications in the treatment of ophthalmic diseases. Nov 20 2025
P1267 CIRC-014 CIRC-014 is an orally bioavailable cyclin A/B RxL macrocyclic inhibitor. CIRC-014 displays robust anti-tumor activity in chemo-resistant small cell lung cancer (SCLC) PDX models and induces SAC activation and apoptosis in vivo. Nov 20 2025
E6608 HSK31858 HSK31858 is a reversible inhibitor of DPP-1. It promotes the amelioration of neutrophilic inflammation, demonstrating efficacy and safety in reducing exacerbation frequency in adults with bronchiectasis. Nov 20 2025
E1963 ARV-393 ARV-393 is a highly potent, orally bioavailable BCL6 PROTAC degrader. ARV-393 promotes rapid BCL6 degradation through the cells ubiquitin-proteasome pathway. ARV-393 demonstrates DC50 and GI50 values <1 nM in numerous DLBCL and BL cell lines. Nov 19 2025
F5072 Cox1 Antibody [N11K4] Nov 12 2025
F4416 PGC1α/β Antibody [H5N22] Nov 12 2025
F4661 Keratin 20 Antibody [L17C14] Nov 12 2025
F4337 Claudin 7 Antibody [M7D16] Nov 12 2025
F4131 c-Fos Antibody [B8E19] Nov 12 2025
F4147 HER2/ErbB2 Antibody [G18G3] Nov 12 2025
F2178 CXCR4 Antibody [G11H20] CXCR4,CXCR-4 Nov 12 2025
E6559 GS-1427 GS-1427 (Emvistegrast) is an oral, small-molecule quinolone derivative that functions as a potent and selective antagonist of α4β7 integrin, with the potential treatment of inflammatory bowel disease. Nov 12 2025
F3893 Phospho-PERK (Thr982) Antibody [A3P5] Nov 10 2025
E6539 SHOC2–RAS PPI-IN-1 SHOC2-RAS PPI-IN-1 (compound 6) is a non-covalent competitive inhibitor that disrupts the SHOC2-RAS protein-protein interaction. It exhibits an IC50 of 0.048 μM and a KD of 0.065 μM against NRASQ61R. The compound inhibits the SMP phosphatase complex, resulting in elevated CRAFS259 phosphorylation and subsequent blockade of the MAPK signaling pathway (evidenced by reduced pMEK and pERK levels). This inhibition induces tumor cell cycle arrest and apoptosis. SHOC2-RAS PPI-IN-1 serves as a research tool for investigating NRASQ61R-mutant malignancies including melanoma and colorectal cancer. Nov 10 2025
F2955 MIF Antibody [M24J2] Nov 10 2025
E6589 2BAct 2BAct is a potent, orally bioavailable eIF2B activator exhibiting high selectivity (EC50 = 33 nM). It mitigates neurological impairments induced by persistent integrated stress response. This compound demonstrates blood-brain barrier penetration with enhanced solubility and pharmacokinetic properties compared to ISRIB trans-isomer. Nov 09 2025
E5972 ZINC00784494 ZINC00784494 is a selective Lipocalin-2 (LCN2) inhibitor that suppresses cell proliferation, decreases viability, and attenuates AKT phosphorylation in SUM149 cells. This compound demonstrates promising research potential for inflammatory breast cancer (IBC) investigations. Nov 03 2025
E6536 Antalarmin hydrochloride Antalarmin hydrochloride is an orally active, non-peptide corticotropin-releasing hormone receptor 1 (CRHR1) antagonist exhibiting a Ki value of 1 nM. This compound inhibits CRH-induced ACTH secretion and attenuates CRH-mediated and novelty-induced anxiety-like behaviors in preclinical models. Additionally, antalarmin hydrochloride demonstrates anti-inflammatory activity in arthritis models and reduces stress-induced gastric ulceration associated with irritable bowel syndrome. Nov 03 2025
E6534 Safusidenib Safusidenib (AB-291; DS-1001) is an orally bioavailable, selective inhibitor of mutant IDH1. It demonstrates potent inhibition against mutant IDH1 while showing minimal activity against the wild-type enzyme. This compound exhibits antitumor effects in chondrosarcoma models. In vitro assays without preincubation, it inhibits IDH1R132H and IDH1R132C with IC50 values of 15 nM and 130 nM, respectively. Nov 03 2025
E6576 Valiltramiprosate ALZ-801 is an orally bioavailable small-molecule β-amyloid (Aβ) anti-oligomer and aggregation inhibitor. As a valine-conjugated prodrug of tramiprosate, it demonstrates significantly enhanced pharmacokinetic properties and gastrointestinal tolerability compared to the parent compound. This agent represents an optimized therapeutic candidate for Alzheimer's disease treatment. Nov 03 2025
E5971 ZINC00640089 ZINC00640089 is a selective Lipocalin-2 (LCN2) inhibitor that suppresses cell proliferation, decreases cell viability, and reduces AKT phosphorylation levels in SUM149 cells. This compound shows promising research potential for inflammatory breast cancer (IBC) studies. Oct 28 2025
E6541 PolQi2 PolQi2 is a PolΘ inhibitor that specifically targets the N-terminal helicase domain of PolΘ, thereby suppressing alt-EJ (alternative end-joining) repair. This compound improves the accuracy and integration efficiency of gene editing across multiple loci and diverse cell lines. Additionally, PolQi2 demonstrates synergistic effects with DNA-PK inhibitors in reducing Cas9-mediated off-target activity. Its application is suitable for gene editing studies. Oct 28 2025
E6522 HRS-9821 PDE3/4-IN-2 (Compound 1) functions as a dual inhibitor targeting both PDE3 and PDE4 enzymes, exhibiting IC50 values of 0.13 nM for PDE3A and 50 nM for PDE4B1. This compound demonstrates potential for investigating PDE-associated pathologies including asthma, chronic obstructive pulmonary disease, sepsis, and nephritis. Oct 22 2025
E1076 Linperlisib Linperlisibis a highly selective, orally bioavailable PI3Kδ inhibitor with an IC50 value of 6.4 nM, as disclosed in patent WO 2015055071 A1 (compound 10). Oct 15 2025
E6577 1-Naphthohydroxamic acid 1-Naphthohydroxamic acid (Compound 2) demonstrates potent and selective inhibition of HDAC8 (IC50 = 14 μM), exhibiting significantly greater selectivity for HDAC8 compared to class I HDAC1 and class II HDAC6 (IC50 >100 μM). This compound does not elevate global histone H4 acetylation levels nor decrease total intracellular HDAC activity. Additionally, 1-naphthohydroxamic acid has been shown to promote tubulin acetylation. Oct 15 2025
F0871 eNOS/NOS Type III Antibody [L17A10] eNOS,eNOS/NOS Type III,NOS3 Oct 13 2025
F2333 Phospho-p70 S6K (Thr421/Ser424) Antibody [E5J12] p70 S6K phospho Thr421 Ser424,Phospho-p70 S6 Kinase (Thr421/Ser424) Oct 13 2025
F2518 Oct4 Antibody [K18A18] Oct3/4,Oct-3/4,Oct4,Oct-4,OCT-4 [POU5F1] Oct 13 2025
F0232 LATS1 Antibody [A5C10] LATS1,LATS1/WARTS Oct 13 2025
F3854 Periostin Antibody [C16F13] Oct 13 2025
F4076 PDGFR α Antibody [E14D18] Oct 13 2025
F4084 β-Catenin Antibody [E8L3] Oct 13 2025
F4087 Phospho-Akt1 (Ser473) Antibody [K10L8] Oct 13 2025
F4181 MMP-2 Antibody [C12L21] Oct 13 2025
F4220 Zap-70 Antibody [E5E23] Oct 13 2025
F4988 PSMA Antibody [A11C13] Oct 13 2025
F3994 LAMP2A Lysosome Marker Antibody [M18B14] Oct 13 2025
F4221 STAT5 Antibody [B9G7] Oct 13 2025
F3245 IRF1 Antibody [H12G6] Oct 13 2025
E1242 Barbadin Barbadin is a selective β-arrestin/β2-adaptin interaction inhibitor with IC50 values of 19.1 μM (β-arrestin1) and 15.6 μM (β-arrestin2). It inhibits agonist-induced endocytosis of β2-adrenergic, V2-vasopressin, and angiotensin-II type-1 receptors. Additionally, Barbadin exhibits pro-apoptotic activity. Oct 12 2025
E6574 NLRP3 NLRP3/aim2-in-2 (compound 8) is a novel potent inhibitor exhibiting species-specific effects on NLRP3 and AIM2 inflammasome-dependent cell death, with an IC50 value of 0.2392 μM. Oct 10 2025
E6573 Neuropathiazol Neuropathiazol is a neuronal differentiation inducer that specifically promotes the neuronal differentiation of multipotent hippocampal neural progenitor cells. Oct 10 2025
E1955 TNG348 TNG348 is an orally bioavailable allosteric inhibitor targeting the ubiquitin-specific protease USP1. It selectively and potently blocks USP1 activity, preventing deubiquitination of proliferative PCNA and FANCD2, which disrupts DNA repair mechanisms. TNG348 demonstrates inhibitory effects against BRCA1/2-mutated and homologous recombination-deficient (HRD) breast and ovarian cancers . Oct 10 2025
E6596 LAP LAP (Lithium phenyl-2,4,6-trimethylbenzoylphosphinate) serves as a free radical initiator. The radicals generated by LAP during bioprinting exhibit potential cytotoxicity and mutagenicity. Furthermore, LAP concentration influences the mechanical strength of 3D-printed scaffolds. The typical concentration range employed for curing is 0.05%-1%. Optimal mechanical properties and biocompatibility are achieved at 0.1% concentration, demonstrating the highest elastic modulus. Sep 29 2025
E6514 BI033 BI033 is a selective inhibitor of BTB and CNC homology 1 (BACH1) specifically binds to BACH1's N-terminal with a Kd of 9.0 uM. It disrupts the BACH1–HDAC1 interaction, enhances H3K27 acetylation at BACH1 target genes, and upregulates angiogenic genes, suggesting its therapeutic potential for myocardial infarction and ischemic vascular disease. Sep 29 2025
E1829 Calderasib (MK-1084) Calderasib (MK-1084) is a selective KRAS G12C inhibitor demonstrating antitumor efficacy. It can be utilized as monotherapy or in combination with pembrolizumab () for oncology research. Sep 25 2025
E7074 Sulfo-NHS-LC-Biotin sodium Sulfo-NHS-LC-Biotin sodium is a biotinylated amine-reactive ester compound that cannot cross the intact blood-retinal barrier. This reagent serves as a useful tool for evaluating vascular permeability in both cerebral and retinal vasculature. Sep 24 2025
E5854 XYD049 XYD049 (compound 7d) is a CRBN-based molecular glue targeting GSPT1 (DC50=19 nM), applicable for studying MYC-driven castration-resistant prostate cancer (CRPC). It demonstrates potent growth inhibition of 22Rv1 cells (IC50=7 nM) and exhibits in vivo antitumor activity. This compound downregulates CRPC-associated oncogenes (AR, AR-v7, PSA, c-Myc) in 22Rv1 cells. Structurally, it consists of: 1) a molecular glue linker (NH2-C5-NH-Boc), 2) a CRBN-recruiting E3 ligase ligand (Thalidomide 4-fluoride), and 3) a GSPT1-targeting moiety (GSPT1 ligand-1). The E3 ligase ligand-linker combination forms conjugate 158. Sep 24 2025
E1968 BBO-8520 BBO-8520 is a covalent small molecule inhibitor that selectively targets KRAS G12C with high oral bioavailability. It functions as both a KRAS G12C (OFF) inhibitor and a blocker of KRAS G12C (ON) signaling. This compound inhibits cellular proliferation by binding to GTP-bound KRAS G12C (ON), thereby preventing RAS-RAF1 interaction and promoting the transition to the inactive (OFF) state. Sep 24 2025
E6407 CD2665 CD2665 is an orally bioavailable selective antagonist of RAR-β and RAR-γ, exhibiting dissociation constants (Kd) of 306 nM for RAR-β and 110 nM for RAR-γ. Sep 24 2025
E6410 Peptide 4 Peptide 4 is a complex synthetic peptide molecule commonly used as a research chemical or therapeutic agent due to its potential to mimic biological peptides and modulate specific molecular targets. Sep 16 2025
S9959 Zotizalkib Zotizalkib(TPX-0131) is a compact macrocyclic potent CNS-penetrant, next-generation inhibitor of wild-type ALK and ALK-resistant mutations with an IC50 of 1.4 nM for wild-type ALK. It exhibits antitumor efficacy and can be used in non–small cell lung cancer research. Sep 14 2025
E4727 TYRA-300 TYRA-300 , a 3-pyridylindazole analog, is a reversible and selective inhibitor of FGFR3 with an IC50 of 11 nM in Ba/F3 cells. It also exhibit potent activity in human bladder cancer cell lines harboring FGFR3 activating fusions or mutations. Sep 14 2025
E6547 crinecerfont crinecerfont (SSR-125543) is a selective antagonist of the corticotropin-releasing factor type 1 receptor (CRF1R). It lowers elevated adrenal androgens and steroid precursors in adolescents with congenital adrenal hyperplasia (CAH), including those with 21-hydroxylase deficiency. Sep 14 2025
E6580 Nusinersen Nusinersen is an 18-mer, 2′-O-(2-methoxyethyl) phosphorothioate antisense oligonucleotide used for treating spinal muscular atrophy (SMA). It binds specifically to the intronic splice silencer N1 (ISS-N1) site in intron 7 of SMN2 pre-mRNA, blocking the binding of splicing repressors hnRNP A1/A2. This promotes inclusion of exon 7 during splicing, restoring full-length SMN protein production in SMA patients. Sep 12 2025
E6581 Mipomersen Mipomersen (ISIS 301012 free base) is an antisense oligonucleotide inhibitor of apolipoprotein B-100 (apoB-100) that causes selective degradation of apoB-100 mRNA, thereby inhibiting protein translation. This leads to reductions in low-density lipoprotein cholesterol (LDL-C) and other apoB-containing lipoprotein levels. Mipomersen is used as an adjunct treatment for homozygous familial hypercholesterolemia (FH). Sep 12 2025
E1887 Sisunatovir hydrochloride Sisunatovir hydrochloride (RV521 hydrochloride) is an orally available and potent inhibitor of the RSV-Fprotein with IC50 values of 1.4 nM and 1.0 nM for RSV A, RSV B, respectively. It effectively reduces RSV viral load and disease severity in humans and has demonstrated a good safety profile in the treatment of an established RSV infection. Sep 07 2025
F0016 V5-Tag Antibody [K5J22] Paramyxovirus SV5 Pk,V5,V5 Epitope Tag,V5 Tag,V5-Probe,V5-Tag Sep 05 2025
F2801 MALT1/MLT Antibody [P2K2] MALT1,MALT1/MLT Sep 05 2025
F2459 Caspase-3 p12 Antibody [N15D21] caspase-3 p11,Caspase-3 p12 Sep 05 2025
F2516 mTOR Antibody [L10A18] Sep 05 2025
E6459 Phaclofen Phaclofen is a selective antagonist of GABAB receptor. Phaclofen is a peripheral and central baclofen antagonist that is used in determining the physiological significance of central and peripheral bicuculline-insensitive receptors with which GABA and (-)-baclofen interact. Sep 03 2025
S8027 GW1929 GW1929 is a potent and selective agonist of PPARγ with a pKi of 8.84 for human PPARγ and pEC50 of 8.56 and 8.27 in human and murine receptors, respectively. It exhibits potential clinical benefits in managing diabetic dyslipidemias and cardiovascular risk factors through its lipid-lowering effects and improved insulin sensitivity mediated by PPARγ activation. Sep 01 2025
E6478 ML115 ML115 is a molecular probe and a highly potent, selective agonist of STAT3 with an EC50 of 2.0 nM. It can be used in research on cancer, wound healing, cardiomyopathy, and inflammatory diseases. Aug 26 2025
E5885 JG-2016 JG-2016 is a potent and selective inhibitor of HAT1, with an IC50 of 14.8 μM and a binding KD of 22.5 μM for the HAT1:Rbap46 complex. It exhibits anti-proliferative activity with EC50 of 10.4 μM, 29.8 μM, and 1.9 μM in HCC1806, FICC1937, and A549 cells, respectively. JG-2016 significantly suppresses tumor growth in an A549 xenograft model. Aug 26 2025
E5817 Sevasemten Sevasemten is a selective, orally active allosteric inhibitor of skeletal muscle myosin that protects skeletal muscle from contraction-induced injury. Sevasemten reduces biomarkers of muscle damage and fibrosis, while enhancing muscle strength and functional activity in models of Duchenne muscular dystrophy. Aug 26 2025
A2173 Anti-mouse L-Selectin (CD62L)-InVivo Anti-mouse L-Selectin (CD62L)-InVivo reacts with mouse CD62L also known as L-selectin and MEL-14. CD62L is a 76 kDa glycoprotein and a member of the selectin family. Aug 22 2025
A2174 Anti-mouse/human CD44-InVivo Anti-mouse/human CD44-InVivo reacts with human and mouse CD44 also known as Hermes, HCAM, and Pgp-1. CD44 is an 80-95 kDa glycoprotein that is expressed on all leukocytes, endothelial cells, hepatocytes, and mesenchymal cells. Aug 22 2025
E5989 PZL-A PZL-A is a activator of mitochondrial DNA (mtDNA) synthesis. PZL-A restores wild-type-like activity to mutant forms of polymerase γ (POLγ) with 160 nM for A467T and 20 nM for G848S. In cellular systems, PZL-A stimulates mtDNA synthesis, promoting oxidative phosphorylation complex biogenesis and improving cellular respiration. PZL-A is promising agent for relieving POLG disease and other severe conditions linked to depletion of mtDNA. Aug 20 2025
E6444 SSTC3 SSTC3 is a potent activator of casein kinase 1α (CK1α) with a Kd of 32 nM that inhibits WNTsignaling with an EC50 of 30 nM. It attenuates CRC cell growth through CK1α-dependent WNT pathway inhibition, offering an improved therapeutic index for targeting WNT-driven tumors. Aug 20 2025
E5992 VLS-1272 VLS-1272 is an orally bioavailable, potent, ATP non-competitive, microtubule-dependent, and highly selective inhibitor of KIF18A with an IC50 of 41 nM. It induces mitotic defects with strong anti-mitotic, anti-cancer, and anti-proliferative effects, leading to dose-dependent tumor growth inhibition and can be used for the study of cancers with high chromosomal instability. Aug 20 2025
E4693 AC-73 AC-73 is a first specific, orally active and potent inhibitor of CD147. It exerts anti-proliferative effects by inducing autophagy and enhancing chemotherapeutic sensitivity in acute myeloid leukemia (AML) cells, while also inhibiting Hepatocellular carcinoma (HCC) mobility and invasion through suppression of the CD147/ERK1/2/STAT3/MMP-2 pathway, making it valuable for AML and HCC research. Aug 20 2025
E5970 PF-07853578 PF-07853578 (Example 11) is a degrader of Patatin-Like Phospholipase Domain-Containing Protein 3(PNPLA3) with an EC50 of 5.2 nM. It may be useful for the treatment and prevention of liver diseases, including fatty liver, nonalcoholic fatty liver disease (NALFD), nonalcoholic steatohepatitis (NASH), liver fibrosis, cirrhosis, and hepatocellular carcinoma. Aug 20 2025
E6502 USP7-IN-1 USP7-IN-1 (Example 2) is a selective and reversible inhibitor of USP7 with an IC50 of 77 Μm and exhibits antiproliferative activity, inhibiting the growth of HCT116 colorectal cancer cells with a GI50 of 67 μM. Aug 20 2025
F3784 RHEB Antibody [L24C4] Aug 19 2025
F3880 NUMB Antibody [D4K1] Aug 19 2025
F3830 CX3CL1/Fractalkine Chemokine Domain Antibody [K3M15] Aug 19 2025
F0603 Phospho-YB1 (Ser102) Antibody [D17A16] Aug 19 2025
F3780 KLF4 Antibody [K21G5] Aug 19 2025
F3225 MCP1 Antibody [M3B19] CCL2 (MCP-1),CCL2/MCP1 Aug 19 2025
F3741 Monocyte + Macrophage Antibody [E17C4] Aug 19 2025
F3764 Phospho-Hsp27 (Ser82) Antibody [M1P19] Hsp27 (phospho S82),Phospho-HSP27 (Ser82),Phospho-HSP27 (Ser82) II Aug 19 2025
E5962 BRD-810 BRD-810 is a potent and highly selective inhibitor of MCL1. BRD-810 targets the BH3-binding pocket of MCL1 and blocks the capturing of pro-apoptotic proteins, thereby rapidly triggering caspase activation in MCL1-dependent cells. It demonstrates potent anti-tumor effects in both hematologic malignancies and solid tumor models. Aug 18 2025
E1566 Ensifentrine Ensifentrine (RPL-554) is a first-in-class dual inhibitor of phosphodiesterase 3 (PDE3) and PDE4 with IC50 values of 0.4 nM and 1479 nM, respectively. Ensifentrine also inhibits lipopolysaccharide-induced tumor necrosis factor alpha release from human monocytes in a concentration-dependent manner. Ensifentrine demonstrates bronchoprotective and anti-inflammatory activities and can be used for chronic obstructive pulmonary disease (COPD) research. Aug 18 2025
E6471 JY-2 JY-2 is a selective and orally active inhibitor of the transcription factor forkhead box O1 (FoxO1). JY-2 suppresses FoxO1-driven transcriptional activity with an IC50 of 22 μM, and also exerts moderate inhibitory effects on FoxO3a and FoxO4. JY-2 also exhibits anti-diabetic properties. Aug 18 2025
E5984 ML339 ML339 is a potent and selective antagonist of CXCR6. ML339 antagonizes CXCL16-induced β-arrestin recruitment and cAMP signaling through the human CXCR6 receptor with IC50 values of 0.3 and 1.4 μM, respectively. ML339 shows no inhibitory activity against CXCR5, CXCR4, and CCR6. ML339 can be used as a potential agent for prostate cancer research. Aug 18 2025
E6477 Taurolithocholic acid Taurolithocholic acid is a taurine-conjugated tertiary bile acid. It induces apoptosis in hepatoma cell lines via caspase-3/7 activation and serves as a model to study the endocrine and metabolic roles of bile acids in enterohepatic circulation and liver physiology. Aug 14 2025
F2823 β Amyloid 1-40 Antibody [G17F9] beta Amyloid 1-40 Aug 14 2025
F3375 β Amyloid 1-42 Antibody [H15J22] Amyloid beta,beta Amyloid,beta-Amyloid,vascular Amyloid 1-42,β-Amyloid Aug 14 2025
F3785 SIRT5 Antibody [G24H6] Aug 14 2025
F4266 PPARα Antibody [P17E1] Aug 14 2025
F3747 PRDM16 Antibody [P2E21] Aug 14 2025
F3720 Pellino 1 Antibody [H22B1] Pellino 1,Pellino-1 Aug 14 2025
F3788 Flotillin 1 Antibody [J14F12] Flotillin 1,Flotillin-1 Aug 14 2025
F3760 PAN TEAD Antibody [A12P9] Pan-TEAD,TEAD4/TEF-1 Aug 14 2025
F3768 RAB10 Antibody [K22D15] Aug 14 2025
F3771 Mitofusin 1 Antibody [D5A17] MFN1,Mfn1/Mitofusin 1,Mitofusin 1,Mitofusin-1 Aug 14 2025
F3786 PAI1 Antibody [E17P19] PAI1,PAI-1,PAI-1/SERPINE1,Serpin E1/PAI-1 Aug 14 2025
F1781 Mast Cell Tryptase Antibody [L14M18] Mast Cell Tryptase,TPSAB1,Tryptase,Tryptase Antibody, Mast Cell Aug 12 2025
E5997 Balinatunfib Balinatunfib (SAR441566) is an oral inhibitor of tumor necrosis factor receptor 1 (TNFR1) signaling. It binds to the central pocket of the soluble TNFα (sTNFα) trimer, alters its configuration, and prevents heterotrimerization with TNFR1 but not TNFR2, thereby blocking TNFR1 signaling. Balinatunfib exhibits anti-inflammatory activity and has the potential for use in autoimmune disease studies. Aug 12 2025
E6400 BSJ-5-63 BSJ-5-63 is a potent PROTAC degrader of CDK12, CDK7, CDK9. BSJ-5-63 decreases the protein expression of CDK12, CDK7, CDK9, RNAPII, Cyclin K, while also suppressing the mRNA expression of BRCA1 and BRCA2. BSJ-5-63 demonstrates anticancer properties and has the potential for the research of prostate cancer. Aug 12 2025
E6500 Lignoceric acid Lignoceric acid is a 24-carbon saturated (24:0) fatty acid. In mammals, it is synthesized during brain development and is found in cerebrosides. The deficient peroxisomal oxidation of very-long-chain fatty acids, contributes to certain syndromes. Lignoceric acid can be used for Zellweger cerebro‐hepato‐renal syndrome and adrenoleukodystrophy research. Aug 12 2025
E6484 E1231 E1231 (1-{4-[2-(5-Methylfuran-2-yl)quinoline-4-carbonyl]piperazin-1-yl}ethan-1-one) is a piperazine 1,4-diamide compound and an oral activator of SIRT1 with an EC50 of 0.83μM. It increases cholesterol efflux and decreases lipid accumulation in macrophages. E1231 regulates cholesterol and lipid metabolism in hyperlipidemic golden hamsters, with potential for atherosclerosis treatment. Aug 11 2025
E6486 VT3989 VT3989 (YAP/TAZ inhibitor-3) is a potent and selective oral inhibitor of TEAD auto-palmitoylation, blocking its interaction with yes-associated protein (YAP). It exhibits antitumor activity and shows potential for treating mesothelioma and solid tumors with NF2 mutations. Aug 11 2025
E6401 Vicadrostat Vicadrostat (compound 29 A) is a potent and selective inhibitor of aldosterone synthase(CYP11B2) with an IC50 of 16 nM. It exhibits potential in renal disease, diabetic nephropathy, cardiovascular diseases and fibrotic disorder research. Aug 07 2025
E5953 (S)-ACE-OH (S)-ACE-OH is a metabolite of the antipsychotic drug acepromazine. (S)-ACE-OH acts as a molecular glue to induce an interaction between the E3 ubiquitin ligase TRIM21 and the nucleoporin NUP98 resulting in degradation of nuclear pore proteins and disruption of nucleocytoplasmic trafficking. It exhibits anti-cancer activity. Aug 07 2025
E6434 BPI-460372 BPI‑460372 is an orally available, covalent, irreversible inhibitor of TEAD 1/3/4 that binds to the cysteine residue in the TEAD palmitoylation pocket, preventing palmitoylation and inhibiting TEAD’s transcriptional activity. Aug 07 2025
E6458 ATF3 inducer 1 ATF3 inducer 1 (Compound 16c) is an achiral molecule that effectively induces ATF3 expression. It suppresses adipogenesis and enhances thermogenesis in an ATF3-dependent manner, improving glucose and lipid profiles in HFD-fed mice. It acts as a potential candidate for metabolic syndrome therapy. Aug 07 2025
E5857 GSK-872 hydrochloride GSK-872 hydrochloride is an inhibitor of RIPK3, which binds the RIP3 kinase domain with an IC50 of 1.8 nM and inhibits kinase activity with an IC50 of 1.3 nM. It exhibits the potential in alleviating early brain injury by inhibiting neuronal necroptosis and HMGB1-mediated inflammation. Aug 07 2025
E8307 Chloroquine dihydrochloride Chloroquine dihydrochloride acts as an inhibitor of autophagy and toll-like receptors (TLRs). Chloroquine dihydrochloride is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Aug 07 2025
E5947 AZ3246 AZ3246 is a selective inhibitor of HPK1 with an IC50 value of <3 nM. AZ3246 induces IL-2 secretion in T cells with an EC50 of 90 nM and demonstrates antitumor activity in in vivo models. Aug 07 2025
E6419 RG6344 RG6344 (RO7276389) is a brain penetrant inhibitor of BRAF which is designed to overcome the MAPK paradoxical activity. RG6344 can be used for the study of BRAF V600-mutant solid tumors, such as colorectal cancer (CRC). Aug 07 2025
E6041 Cephalexin hydrochloride Cephalexin (hydrochloride, Cefalexin hydrochloride) is a potent, orally active cephalosporin antibiotic with broad-spectrum activity. It acts by binding to penicillin-binding proteins (PBPs), thereby disrupting bacterial cell wall synthesis. Cephalexin hydrochloride demonstrates antibacterial activity against a wide variety of gram-positive and gram-negative bacteria. Aug 07 2025
E6482 STAT3-IN-12 STAT3-IN-12 is a potent inhibitor of STAT3signaling, by effectively blocking IL-6-induced activation of the JAK/STAT3 pathway. STAT3-IN-12 suppresses cancer cell proliferation and migration, while promoting apoptosis and inducing cell cycle arrest. Aug 07 2025
F2509 VEGFD Antibody [K3P16] Aug 04 2025
F3242 BACE1 Antibody [L19L22] BACE, BACE1 Aug 04 2025
F3323 AP2S1 Antibody [L13B7] Aug 04 2025
F3338 Smad1 Antibody [K19G18] Aug 04 2025
F3358 Phospho-Estrogen Receptor α (Ser118) Antibody [L4E1] Estrogen Receptor alpha (phospho S118),Phospho-Estrogen Receptor α (Ser118) Aug 04 2025
F3379 Fos B Antibody [G14F16] Fos B,FosB Aug 04 2025
F3447 PSF1 Antibody [E5F3] Aug 04 2025
F3600 SEP15 Antibody [A2N16] Aug 04 2025
F3628 HACE1 Antibody [A17B18] Aug 04 2025
E5921 ZSA-51 ZSA-51 is a potent oral agonist of STING. It exhibits potent antitumor efficacy in colon and pancreatic cancer, with superior oral PK, low toxicity, and immune microenvironment remodeling in tumors and lymph nodes. Aug 04 2025
E5766 DC-Y13-27 DC-Y13-27, a derivative of DC-Y13, is an inhibitor of YTHDF2 with a KD of 37.9 μM. It also upregulates FOXO3 and TIMP1 while downregulating MMP1, MMP3, MMP7, and MMP9. Additionally, it enhances the antitumor effects of radiotherapy and radio-immunotherapy and is implicated in intervertebral disc degeneration pathogenesis research. Aug 04 2025
E1928 Azelaprag Azelaprag (AMG 986) is a potent agonist of apelin receptor (APJ) with an EC50 of 0.32 nM. It exhibits potential and can be used in Heart failure (HF) research. Aug 04 2025
E5951 iZMYND8-34 iZMYND8-34 is a selective inhibitor of the histone reader ZMYND8 that blocks its histone recognition. Targeting ZMYND8 effectively suppresses antiandrogen-induced neuroendocrine transdifferentiation in prostate cancer, offering a promising approach to prevent neuroendocrine prostate cancer (NEPC) development. Jul 31 2025
E4758 ACBI3 ACBI3 is a selective and potent PROTAC degrader of pan-KRAS that promotes VHL engagement, ternary complex formation, and E3 ligase-dependent KRAS degradation with high proteome-wide selectivity. It demonstrates strong anti-tumor activity, resulting in durable pathway modulation and tumor regressions in KRAS driven cancers. Jul 31 2025
E5942 UNC9426 UNC9426 (compound 12) is a potent and orally bioavailable inhibitor of TYRO3 with an IC50 of 2.1 nM. It reduces platelet aggregation without prolonging bleeding time and effectively suppresses TYRO3-mediated signalling pathways in tumor cells and macrophages. Jul 31 2025
E6073 Solifenacin hydrochloride Solifenacin hydrochloride (YM905 hydrochloride) is an antagonist of muscarinic receptor used for the treatment of overactive bladder. It exhibits pKi values of approximately 7.6, 6.9, and 8.0 for the M1, M2, and M3 muscarinic receptors, respectively, in radioligand binding assays. Jul 31 2025
E4741 AZD4144 AZD4144 (Compound 25) is a potent and selective inhibitor of the NLRP3 inflammasome with an IC50 of 76 nM in the nigericin-triggered speck formation assay. It binds directly to the NACHT domain of NLRP3, stabilizing its inactive conformation to prevent inflammasome activation. AZD4144 also inhibits LPS/ATP-induced release of pro-inflammatory cytokines IL-1β and IL-18 in mice with an IC50 of 54 nM and exhibits potential for treating inflammatory diseases. Jul 31 2025
E6067 Frovatriptan succinate hydrate Frovatriptan succinate hydrate ((R)-Frovatriptan succinate hydrate, SB 209509 succinate) is a potent, selective and orally active agonist of 5-HT1B with pEC50 value of 8.2 and 5-HT1D receptor. It displays >10-fold selectivity for 5-HT1B and 5-HT1D over 5-HT1A, 5-HT1F, and 5-HT7 and a >1000-fold selectivity over other 5-HT, dopamine, histamine H1, and α1-adrenoceptor. Jul 28 2025
E1609 NVP-CLR457 NVP-CLR457 is an orally active, potent, and balanced inhibitor of pan-class I PI3K. NVP-CLR457 exhibits IC50 values of 12 ± 1.5 nM, 8.3 ± 1.0 nM, 8.3 ± 2.0 nM, 230 ± 31 nM, for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ. It shows a clear dose-dependent PK/PD/efficacy relationship and demonstrates antitumor activity. Jul 28 2025
E6460 Phenamil methanesulfonate Phenamil methanesulfonate, is a potent and less reversible inhibitor of epithelial sodium channel (ENaC) with an IC50 of 400 nM. Phenamil methanesulfonate is also a competitive inhibitor of TRPP3 and inhibits TRPP3-mediated Ca2+ transport with an IC50 of 140 nM in a Ca2+ uptake assay. Phenamil methanesulfonate is used for the research of cystic fibrosis lung disease. Jul 28 2025
E5969 AZD2389 AZD2389 is a potent, orally active, and selective inhibitor of fibroblast activation protein (FAP) with the potential to treat metabolic dysfunction-associated steatohepatitis. Jul 27 2025
E4605 Copanlisib dihydrochloride Copanlisib dihydrochloride (BAY 80-6946 dihydrochloride) is a selective and potent inhibitor of pan-class I PI3K. It significantly inhibits the catalytic activity of class I PI3K isoforms α, β, γ, and δ with IC50 of 0.5, 3.7, 6.4, and 0.7 nM, respectively. BAY 80-6946 exhibits potent antitumor activity in multiple cell-line–derived and patient-derived xenograft tumor models. Jul 27 2025
E5883 AM-9022 AM-9022 is an orally active, potent, and selective inhibitor of KIF18A, a mitotic kinesin motor protein critical for chromosome alignment and segregation. It exhibits significant anti-cancer effects in human breast and ovarian tumor models. Jul 25 2025
E4658 Tilfrinib Tilfrinib (Compound 4f) is a potent and selective inhibitor of the tyrosine-protein kinase Brk/PTK6, with an IC50 of 3.15 nM. It demonstrates significant anti-proliferative activity against breast cancer cell lines MCF7, HS-578T, and BT-549. Jul 25 2025
E5863 α-NETA α-NETA is a potent, irreversible and noncompetitive inhibitor of choline acetyltransferase (ChA) with an IC50 of 9 μM. It is also a potent antagonist of ALDH1A1, CMKLR1, and G9a histone methyltransferase with an IC50 of 0.04 µM, 0.38 µM, and 0.50 µM, respectively. It exhibits anti-cancer activity and may be beneficial in preventing or treating multiple sclerosis (MS). Jul 23 2025
E6408 CD1530 CD1530 is a potent and selective agonist of RARγ receptor with Ki values of 150 nM. It is a potent inhibitor of heterotopic ossification (HO) and may be effective against congenital HO, with potential use in research on psoriasis, acne, photoaging, and cancer. Jul 23 2025
E5960 PRDX1-IN-1 PRDX1-IN-1 is a celastrol-ligustrazine hybrid and a potent inhibitor of peroxiredoxin 1 (PRDX1) with an IC50 of 0.164 μM. It induces ROS accumulation, inhibits cancer cell growth and metastasis, and exhibits strong antitumor efficacy, making it a promising candidate for lung cancer therapy. Jul 23 2025
S9958 CB-6644 CB-6644 is an allosteric and selective inhibitor of the RUVBL1/2 complex, it blocks the ATPase activity of RUVBL1/2 with an IC50 of 15 nM. It exhibits anti-cancer activity and demonstrates the therapeutic potential of targeting RUVBLs in the treatment of cancer. Jul 20 2025
E6463 Glycerophospholipids, cephalins Glycerophospholipids, cephalins are amphipathic molecules and essential components of neural membranes that are required for neural membrane structure and the proper function of integral membrane proteins, receptors, transporters, and ion channels. They also participate in apoptosis, regulate transporter and membrane-bound enzyme activities, and also serve as storage depots for lipid mediators and are useful in neurological disorder research, including Alzheimer's disease. Jul 17 2025
E5928 FAZ-3532 FAZ-3532 is a potent inhibitor of G3BP that binds to G3BP1 with a Kd of 0.54 μM, inhibiting co-condensation of G3BP1, Caprin1, and RNA, and blocking stress granule formation in cells. It specifically targets the protein–protein interaction within the NTF2L domain of G3BP1 without affecting its dimerization or RNA-binding, making it a useful tool to study the immunological role of stress granules during viral infection. Jul 17 2025
E4708 Etoposide phosphate Etoposide phosphate a phosphate ester proagent of etoposide, is a selective inhibitor of topoisomerase II and a potent anti-cancer chemotherapy agent. This compound also induces cell cycle arrest, apoptosis, and autophagy. Jul 15 2025
E8308 Alpelisib hydrochloride Alpelisib hydrochloride is a potent and selective inhibitor of PI3Kα with an IC50 of 0.005 μM, 1.2 μM, 0.29 μM, 0.25 μM for p110α, p110β, p110δ, p110γ, respectively. It exhibits good efficacy in inhibiting the growth of PI3Ka driven tumors and can be used in cancer research. Jul 15 2025
E6435 CORM-401 CORM-401 is a water-soluble Carbon monoxide-releasing molecule that exhibits antioxidant and cytoprotective effects under oxidative stress conditions, including TNF-α/CHX and H₂O₂-induced damage. It induces nitric oxide production, activates the pentose phosphate pathway, and triggers distinct calcium signaling patterns, contributing to the regulation of endothelial function. Jul 15 2025
F3517 E-Cadherin Antibody [P11M9] E Cadherin,E-Cadherin,Uvomorulin/E-Cadherin Jul 14 2025
F3611 Clusterin Antibody [F10K16] Clusterin,Clusterin-α Jul 14 2025
F3695 LIF Antibody [G1M1] Jul 14 2025
F3757 Syk Antibody [M21H12] Jul 14 2025
F3640 Heme Oxygenase 1 Antibody [G7A14] Heme Oxygenase 1,Heme Oxygenase 1/HMOX1,HMOX1,HO-1 Jul 14 2025
F3879 HDAC1 Antibody [C7G4] Jul 14 2025
F0436 Insulin Antibody [K13G15] Jul 14 2025
F0646 Pdx1 Antibody [F18P8] Jul 14 2025
P1257 Nangibotide TFA Nangibotide TFA is a synthetic peptide that specifically inhibits the TREM‐1 (triggering receptor expressed on myeloid cells‐1) pathway by acting as a decoy receptor to block its activation. It reduces excessive inflammation, restores vascular function, and improves survival in animal models of septic shock. Jul 14 2025
E6425 VRK-IN-1 VRK-IN-1 is a potent and selective inhibitor of vaccinia-related kinase 1 (VRK1) with an IC50 of approximately 150 nM. It also facilitates H4 deacetylation (reducing H4K16 acetylation) and promotes the accumulation of DNA strand breaks while preventing progression of the DNA repair process. Jul 14 2025
E1521 SHR2554 SHR2554 is an inhibitor of EZH2. SHR2554 exhibits anti-tumor activity with IC50 values ranging from 0.365 to 3.001 μM in a dose-dependent manner, in T-cell lymphoma (TCL) by reducing H3K27me3 levels. Jul 14 2025
S9941 Emzadirib Emzadirib, an inhibitor of RAD51, exhibits a reduction in RAD51 foci. This compound displays significant anti-tumor activity with tumor growth inhibition in in vivo and in vitro models. Jul 14 2025
E1767 HX531 HX531 is an orally active antagonist of RXR. This compound enhances activation of the p53–p21Cip1 pathway and abrogates the anti-apoptotic effects of all-trans-retinoic acid (t-RA). It exhibits anti-obesity, anti-diabetic, and anti-melanoma properties. Jul 14 2025
F2703 HSP90α Antibody [F18G3] Jul 14 2025
F3548 PTEN Antibody [J22G2] Jul 14 2025
F3269 Arginase 1 Antibody [B11F1] ARG1/Arignase 1,Arginase 1,Arginase 1/ARG1/liver Arginase,Arginase I,Arginase-1,Liver Arginase Jul 14 2025
F3912 Phospho-JNK (Thr183) Antibody [D9B9] Jul 14 2025
F2822 HLA DR + DP + DQ Antibody [G22B16] HLA DR + DP + DQ,HLA-DR, DP, DQ Jul 10 2025
F3461 VAV3 Antibody [J5F22] Jul 10 2025
F2971 Cathepsin L/V/K/H Antibody [H17P9] Jul 10 2025
F2978 Angiotensinogen Antibody [F19A5] Jul 10 2025